Stephen Fochios

Recent Posts

Attend "Core Components for Contamination Prevention & Control in Biopharma Manufacturing Operations"

Posted by Stephen Fochios

On April 4th, 2017, EG Life Sciences will host a breakfast event at MassBio that will feature Gary C. du Moulin, Ph.D., M.P.H., RAC who will present "Core Components for Contamination Prevention and Control in Biopharmaceutical Manufacturing Operations." Gary recently retired as Senior Director of Quality Aseptic Control for Genzyme (a Sanofi company) where he participated in the development and execution of robust quality systems for Genzyme's products including biologics and cell based therapies.

Read More »

Who's leading in biotech in 2017? East Coast vs. West Coast

Posted by Stephen Fochios

California and Massachusetts are always mentioned together when speaking about the leading life sciences clusters in the US. They frequently share the number one and number two spots on the many lists that are published in the scientific community. The reason? The abundance of world class educational institutions in these areas give companies easy access to top level talent.

Read More »

How to Handle Out of Specification (OOS) Results

Posted by Stephen Fochios

Your cold room just went down: now what?

Read More »

Preparing for Successful Pre-Approval Inspections (PAI)

Posted by Stephen Fochios

What is a Pre-Approval Inspection? For pharmaceutical companies, this FDA inspection is intended to determine whether their facilities, manufacturing processes and controls used to produce and package drug products are adequate to ensure the safety and quality of their products. The FDA wants assurance that problems that arise during the drug manufacturing process are investigated properly and that quality systems are in place to document and remediate these issues in a timely manner.

Read More »

The FDA is On-Site! Checklist for FDA Site Inspections

Posted by Stephen Fochios

In my recent blog post entitled Prepping for a Successful FDA Inspection, we discussed the importance of having a Site Inspection Readiness Team on hand that is always “at the ready” for FDA visits, regardless of whether the visits are scheduled or unannounced. But what happens once the inspectors arrive? You should have a checklist on-hand for the key logistical considerations.

Read More »

Prepping for a Successful FDA Inspection: Site Inspection Readiness Team

Posted by Stephen Fochios

For pharmaceutical, medical device and biotech companies, being always “at the ready” for FDA inspections is an absolute necessity. While some inspections are predetermined, others are surprise visits so it’s critical to have a team and a process in place to ensure you can respond to every inquiry effectively.

Read More »

FDA Form 483 and Warning Letters: What's the difference?

Posted by Stephen Fochios

When the FDA comes in to inspect a pharmaceutical or biotechnology company’s manufacturing facilities they can either alert the company ahead of time or show up unannounced. After the inspection is over the FDA can send what is called an FDA form 483 or a warning letter. There are differences and various consequences depending on how these are both handled.

Read More »

Subscribe to our Blog

Popular Posts

Popular Posts